 | |
| Clinical data | |
|---|---|
| Pronunciation | loo" soo trom' boe pag |
| Trade names | Mulpleta, Mulpleo |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618043 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C29H32Cl2N2O5S |
| Molar mass | 591.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) | |
Lusutrombopag, sold under the brand nameMulpleta among others, is amedication that has been developed for certain conditions that lead tothrombocytopenia (abnormally lowplatelet counts) such as thrombocytopenia associated withchronic liver disease in patients prior to elective invasive procedures.[1] It is being manufactured in Philadelphia, PA and marketed in Japan byShionogi.[2][3][4] It was approved by the U.S.Food and Drug Administration (FDA) in July 2018, and NICE in January 2020.[5][6]
It was approved for medical use in the European Union in February 2019.[7]
 | Thisdrug article relating to theblood andblood forming organs is astub. You can help Wikipedia byexpanding it. |
